MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Wei Wang(Capital Medical University), Ruiwen Zhang(Center for Excellence in Molecular Cell Science), Frank McKeon(University of Houston), Wěi Li(Shougang (China)), Yi Du(University of Houston), Wa Xian(University of Houston), Josef F. Fowler(University of Houston), Jia Zhou(Io Therapeutics (United States)), Hannah T. Sang(University of Houston), Najah Albadari(University of Tennessee Health Science Center)
Pharmacological Reviews
March 15, 2024
10.1124/pharmrev.123.001026
Cited by 127

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416
The MDM2-p53 pathway revisited
|Journal of Biomedical Research|2013|410